BACKGROUND: In a previous linkage study of schizophrenia that included Taiwanese samples, the marker D22S278 (22q12.3) was significantly linked to schizophrenia (p = .001). METHODS: We conducted fine mapping of the implicated genomic region, with 47 validated single nucleotide polymorphism (SNP) markers around 1 Mb of D22S278, in a Taiwanese sample of 218 pedigrees with at least 2 siblings affected with schizophrenia. We examined the association of these SNPs and their haplotypes with schizophrenia and with subgroups defined by the presence and absence of deficits in sustained attention as assessed by undegraded and degraded continuous performance tests (CPTs). We also examined subgroups defined by deficits in categories achieved in the Wisconsin Card Sort Test (WCST). RESULTS: Three of five candidate vulnerability genes (RASD2, APOL5, MYH9, EIF3S7, and CACNG2), which had marginally significant associations with schizophrenia, had significant associations with schizophrenic patients who did not have deficits in sustained attention on the undegraded CPT (RASD2 gene SNP rs736212; p = .0008 with single locus analysis) and the degraded CPT (MYH9 gene haplotype 1-1-1-1 of SNP rs3752463 - rs1557540 - rs713839 - rs739097; p = .0059 with haplotype analysis). We also found a significant association for patients who showed no deficits in executive function as measured by categories achieved in the WCST (CACNG2 gene haplotype 2-1-1-1 of SNP rs2267360 - rs140526 - rs1883987 - rs916269; p = .0163 with haplotype analysis). CONCLUSIONS: The genes RASD2, MYH9, and CACNG2 might be vulnerability genes for neuropsychologically defined subgroups of schizophrenic patients.
BACKGROUND: In a previous linkage study of schizophrenia that included Taiwanese samples, the marker D22S278 (22q12.3) was significantly linked to schizophrenia (p = .001). METHODS: We conducted fine mapping of the implicated genomic region, with 47 validated single nucleotide polymorphism (SNP) markers around 1 Mb of D22S278, in a Taiwanese sample of 218 pedigrees with at least 2 siblings affected with schizophrenia. We examined the association of these SNPs and their haplotypes with schizophrenia and with subgroups defined by the presence and absence of deficits in sustained attention as assessed by undegraded and degraded continuous performance tests (CPTs). We also examined subgroups defined by deficits in categories achieved in the Wisconsin Card Sort Test (WCST). RESULTS: Three of five candidate vulnerability genes (RASD2, APOL5, MYH9, EIF3S7, and CACNG2), which had marginally significant associations with schizophrenia, had significant associations with schizophrenicpatients who did not have deficits in sustained attention on the undegraded CPT (RASD2 gene SNP rs736212; p = .0008 with single locus analysis) and the degraded CPT (MYH9 gene haplotype 1-1-1-1 of SNP rs3752463 - rs1557540 - rs713839 - rs739097; p = .0059 with haplotype analysis). We also found a significant association for patients who showed no deficits in executive function as measured by categories achieved in the WCST (CACNG2 gene haplotype 2-1-1-1 of SNP rs2267360 - rs140526 - rs1883987 - rs916269; p = .0163 with haplotype analysis). CONCLUSIONS: The genes RASD2, MYH9, and CACNG2 might be vulnerability genes for neuropsychologically defined subgroups of schizophrenicpatients.
Authors: Nirmal Vadgama; Alan Pittman; Michael Simpson; Niranjanan Nirmalananthan; Robin Murray; Takeo Yoshikawa; Peter De Rijk; Elliott Rees; George Kirov; Deborah Hughes; Tomas Fitzgerald; Mark Kristiansen; Kerra Pearce; Eliza Cerveira; Qihui Zhu; Chengsheng Zhang; Charles Lee; John Hardy; Jamal Nasir Journal: Eur J Hum Genet Date: 2019-03-18 Impact factor: 4.246
Authors: Tejas S Bhojraj; Vaibhav A Diwadkar; John A Sweeney; Konasale M Prasad; Shaun M Eack; Debra M Montrose; Matcheri S Keshavan Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2010-01-29 Impact factor: 5.067
Authors: Stephanie Nissen; Sherri Liang; Tatyana Shehktman; John R Kelsoe; Tiffany A Greenwood; Caroline M Nievergelt; Rebecca McKinney; Paul D Shilling; Erin N Smith; Nicholas J Schork; Cinnamon S Bloss; John I Nurnberger; Howard J Edenberg; Tatiana Foroud; Daniel L Koller; Elliot S Gershon; Chunyu Liu; Judith A Badner; William A Scheftner; William B Lawson; Evaristus A Nwulia; Maria Hipolito; William Coryell; John Rice; William Byerley; Francis J McMahon; Wade H Berrettini; James B Potash; Peter P Zandi; Pamela B Mahon; Melvin G McInnis; Sebastian Zöllner; Peng Zhang; David W Craig; Szabolics Szelinger; Thomas B Barrett; Thomas G Schulze Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2012-10-04 Impact factor: 3.568
Authors: Daniela Vitucci; Annabella Di Giorgio; Francesco Napolitano; Barbara Pelosi; Giuseppe Blasi; Francesco Errico; Maria Teresa Attrotto; Barbara Gelao; Leonardo Fazio; Paolo Taurisano; Anna Di Maio; Valentina Marsili; Massimo Pasqualetti; Alessandro Bertolino; Alessandro Usiello Journal: Neuropsychopharmacology Date: 2015-07-31 Impact factor: 7.853